FullCircle Wealth’s Tempest Therapeutics TPST Stock Holding History

FullCircle Wealth’s Portfolio TPST Stock Details TPST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-4,769	Closed	-$68.2K	–	236
2024 Q3	$68.2K	Buy	+4,769	New	+$97.7K	0.03%	184

Other funds holding TPST

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

FullCircle Wealth's TPST Position: Q4 2024 in Review

FullCircle Wealth sold out of Tempest Therapeutics (TPST) in Q4 2024, closing a stake of 4,769 shares — an estimated $68.2K sold.

FullCircle Wealth first reported a position in TPST in Q3 2024 and held it in 1 quarter. The position peaked at $68.2K in Q3 2024. 33 funds tracked by Wall St. Rank hold TPST as of Q4 2024.

FullCircle Wealth reported no remaining Tempest Therapeutics position as of Q4 2024 after selling out during the quarter.
FullCircle Wealth sold 4,769 Tempest Therapeutics shares in Q4 2024, an estimated $68.2K.
FullCircle Wealth first reported a position in Tempest Therapeutics in Q3 2024 and held it in 1 quarter.
FullCircle Wealth's Tempest Therapeutics position peaked at $68.2K in Q3 2024.
33 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q4 2024.

Based on FullCircle Wealth's 13F filing for Q4 2024, filed 14 Feb 2025.